Vaxart

VXRT · OTC

$0.49+$0.0145 (+3.05%)TodayMarket closed · Oct 20, 3:54 PM ET

Prev close $0.4755

Latest news

Press releaseOct 19, 8:00 AM ETGlobe Newswire
Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
Press releaseOct 8, 8:40 AM ETGlobe Newswire
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
Press releaseAug 26, 4:07 PM ETGlobe Newswire
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
Press releaseAug 6, 4:05 PM ETGlobe Newswire
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
Press releaseJul 17, 4:05 PM ETGlobe Newswire
Vaxart Announces Results of Annual Meeting of Stockholders
Press releaseJul 6, 4:01 PM ETGlobe Newswire
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
Press releaseJul 1, 4:00 PM ETGlobe Newswire
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Press releaseJun 26, 8:00 AM ETGlobe Newswire
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Press releaseJun 25, 8:00 AM ETGlobe Newswire
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Press releaseJun 16, 8:00 AM ETGlobe Newswire
Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
NewsMay 7, 4:08 PM ET
Vaxart Q1 EPS $0.02 Beats $(0.01) Estimate, Sales $39.227M Miss $65.500M Estimate
Press releaseMay 7, 4:05 PM ETGlobe Newswire
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
NewsMar 12, 4:54 PM ET
Vaxart Q4 EPS $0.24 Beats $(0.05) Estimate, Sales $104.239M Beat $69.700M Estimate
Press releaseNov 13, 4:05 PM ETGlobe Newswire
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
NewsNov 12, 2:04 PM ET
A Look at Vaxart's Upcoming Earnings Report
Press releaseNov 5, 4:01 PM ETPRNewswire
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
Press releaseNov 5, 4:00 PM ETPRNewswire
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Press releaseAug 13, 4:05 PM ETGlobe Newswire
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
NewsAug 12, 3:02 PM ET
Vaxart's Earnings: A Preview
Press releaseJul 8, 7:00 AM ETGlobe Newswire
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
NewsJul 1, 8:07 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseJun 30, 6:45 AM ETBusiness Wire
Vicarious Surgical Announces Election of New Directors
NewsJun 11, 5:56 AM ETRishabh Mishra
US Stocks Likely To Open Lower Ahead Of May Inflation Report: S&P 500 Still In A 31-Month-Long Bull Market, 'Better Times Are Coming,' Says Expert
Press releaseMay 13, 4:05 PM ETGlobe Newswire
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
NewsMay 13, 4:32 AM ET
Earnings Scheduled For May 13, 2025
NewsMay 12, 4:04 PM ET
Insights Ahead: Vaxart's Quarterly Earnings
Press releaseMay 5, 8:00 AM ETGlobe Newswire
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress
Press releaseMar 20, 4:01 PM ETGlobe Newswire
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
NewsNov 12, 1:19 PM ET
Earnings Preview For Vaxart

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors

Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

Vaxart Announces Results of Annual Meeting of Stockholders

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements

Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart Q1 EPS $0.02 Beats $(0.01) Estimate, Sales $39.227M Miss $65.500M Estimate

Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

Vaxart Q4 EPS $0.24 Beats $(0.05) Estimate, Sales $104.239M Beat $69.700M Estimate

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

A Look at Vaxart's Upcoming Earnings Report

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

Vaxart's Earnings: A Preview

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Vicarious Surgical Announces Election of New Directors

US Stocks Likely To Open Lower Ahead Of May Inflation Report: S&P 500 Still In A 31-Month-Long Bull Market, 'Better Times Are Coming,' Says Expert

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

Earnings Scheduled For May 13, 2025

Insights Ahead: Vaxart's Quarterly Earnings

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Earnings Preview For Vaxart